{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:26:03Z","timestamp":1786987563542,"version":"build-2736575974"},"reference-count":87,"publisher":"MathDoc\/Centre Mersenne","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Rituximab was the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma, mantle-cell lymphoma, and diffuse large B-cell lymphoma in untreated or relapsing patients. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, R-CHOP, has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. The role of radio-labelled antibodies is still to be defined.<\/jats:p>","DOI":"10.1016\/j.crvi.2005.12.006","type":"journal-article","created":{"date-parts":[[2006,3,21]],"date-time":"2006-03-21T07:49:17Z","timestamp":1142927357000},"page":"241-254","source":"Crossref","is-referenced-by-count":39,"title":["Monoclonal antibody as therapy for malignant lymphomas"],"prefix":"10.5802","volume":"329","author":[{"given":"Bertrand","family":"Coiffier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3842","published-online":{"date-parts":[[2006,3,20]]},"reference":[{"key":"key2025102316275417624_1","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1200\/JCO.2005.05.015","article-title":"State-of-the-art therapeutics: Diffuse large B-cell lymphoma","volume":"23","author":"Coiffier, B.","year":"2005","unstructured":"[1] Coiffier, B. State-of-the-art therapeutics: Diffuse large B-cell lymphoma, J. Clin. Oncol., Volume 23 (2005), pp. 6387-6393","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1517\/14796694.1.3.297","article-title":"Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma","volume":"1","author":"Traulle, C.","year":"2005","unstructured":"[2] Traulle, C.; Coiffier, B. Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma, Fut. Oncol., Volume 1 (2005), pp. 297-306","journal-title":"Fut. Oncol."},{"key":"key2025102316275417624_3","first-page":"484","article-title":"First-line treatment of follicular lymphoma in the era of monoclonal antibodies","volume":"3","author":"Coiffier, B.","year":"2005","unstructured":"[3] Coiffier, B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies, Clin. Adv. Hematol. Oncol., Volume 3 (2005), pp. 484-491","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"key2025102316275417624_4","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: Ways to improve rituximab efficacy","volume":"104","author":"Cartron, G.","year":"2004","unstructured":"[4] Cartron, G.; Watier, H.; Golay, J.; Solal-Celigny, P. From the bench to the bedside: Ways to improve rituximab efficacy, Blood, Volume 104 (2004), pp. 2635-2642","journal-title":"Blood"},{"key":"key2025102316275417624_5","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.onc.1208349","article-title":"Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mab) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention","volume":"24","author":"Jazirehi, A.R.","year":"2005","unstructured":"[5] Jazirehi, A.R.; Bonavida, B. Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mab) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention, Oncogene, Volume 24 (2005), pp. 2121-2143","journal-title":"Oncogene"},{"key":"key2025102316275417624_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2005.02720.x","article-title":"Rituxan (anti-cd20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis","volume":"139","author":"Janas, E.","year":"2005","unstructured":"[6] Janas, E.; Priest, R.; Wilde, J.I.; White, J.H.; Malhotra, R. Rituxan (anti-cd20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis, Clin. Exp. Immunol., Volume 139 (2005), pp. 439-446","journal-title":"Clin. Exp. Immunol."},{"key":"key2025102316275417624_7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, idec-c2b8)","volume":"94","author":"Winkler, U.","year":"1999","unstructured":"[7] Winkler, U.; Jensen, M.; Manzke, O.; Schulz, H.; Diehl, V.; Engert, A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, idec-c2b8), Blood, Volume 94 (1999), pp. 2217-2224","journal-title":"Blood"},{"key":"key2025102316275417624_8","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng, W.K.","year":"2001","unstructured":"[8] Weng, W.K.; Levy, R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma, Blood, Volume 98 (2001), pp. 1352-1357","journal-title":"Blood"},{"key":"key2025102316275417624_9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.thj.6200133","article-title":"Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment","volume":"2","author":"Bienvenu, J.","year":"2001","unstructured":"[9] Bienvenu, J.; Chvetzoff, R.; Salles, G.; Balter, C.; Tilly, H.; Herbrecht, R.; Morel, P.; Lederlin, P.; Solal-Celigny, P.; Audhuy, B.; Christian, B.; Gabarre, J.; Casasnovas, O.; Marit, G.; Sebban, C.; Coiffier, B. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment, Hematol. J., Volume 2 (2001), pp. 378-384","journal-title":"Hematol. J."},{"key":"key2025102316275417624_10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene","volume":"99","author":"Cartron, G.","year":"2002","unstructured":"[10] Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene, Blood, Volume 99 (2002), pp. 754-758","journal-title":"Blood"},{"key":"key2025102316275417624_11","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment c receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng, W.K.","year":"2003","unstructured":"[11] Weng, W.K.; Levy, R. Two immunoglobulin G fragment c receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J. Clin. Oncol., Volume 21 (2003), pp. 3940-3947","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_12","doi-asserted-by":"crossref","first-page":"170a","DOI":"10.1182\/blood.V104.11.590.590","article-title":"Evidence for Fc<span class=\"italique\">\u03b3<\/span> receptor IIIa-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy","volume":"104","author":"Boettcher, S.","year":"2004","unstructured":"[12] Boettcher, S.; Pott, C.; Ritgen, M.; Hiddemann, W.; Unterhalt, M.; Kneba, M. Evidence for Fc\u03b3 receptor IIIa-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy, Blood, Volume 104 (2004), p. 170a (Abstract 590)","journal-title":"Blood"},{"key":"key2025102316275417624_13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.beha.2004.11.001","article-title":"Radio-immunotherapy in low-grade non-Hodgkin's lymphoma","volume":"18","author":"Lemieux, B.","year":"2005","unstructured":"[13] Lemieux, B.; Coiffier, B. Radio-immunotherapy in low-grade non-Hodgkin's lymphoma, Best Pract, Res. Clin. Haematol., Volume 18 (2005), pp. 81-95","journal-title":"Best Pract, Res. Clin. Haematol."},{"key":"key2025102316275417624_14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2002-06-1793","article-title":"Radioimmunotherapy of non-Hodgkin lymphomas","volume":"101","author":"Cheson, B.D.","year":"2003","unstructured":"[14] Cheson, B.D. Radioimmunotherapy of non-Hodgkin lymphomas, Blood, Volume 101 (2003), pp. 391-398","journal-title":"Blood"},{"key":"key2025102316275417624_15","first-page":"1507","article-title":"Radioimmunotherapy of b-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice","volume":"43","author":"Juweid, M.E.","year":"2002","unstructured":"[15] Juweid, M.E. Radioimmunotherapy of b-cell non-Hodgkin's lymphoma: From clinical trials to clinical practice, J. Nucl. Med., Volume 43 (2002), pp. 1507-1529","journal-title":"J. Nucl. Med."},{"key":"key2025102316275417624_16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1054-3589(04)51009-8","article-title":"Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma","volume":"51","author":"Rosenblum, M.","year":"2004","unstructured":"[16] Rosenblum, M. Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma, Adv. Pharmacol., Volume 51 (2004), pp. 209-228","journal-title":"Adv. Pharmacol."},{"key":"key2025102316275417624_17","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance","volume":"22","author":"Smith, M.R.","year":"2003","unstructured":"[17] Smith, M.R. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance, Oncogene, Volume 22 (2003), pp. 7359-7368","journal-title":"Oncogene"},{"key":"key2025102316275417624_18","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1073\/pnas.0437875100","article-title":"Variation in gene expression patterns in follicular lymphoma and the response to rituximab","volume":"100","author":"Bohen, S.P.","year":"2003","unstructured":"[18] Bohen, S.P.; Troyanskaya, O.G.; Alter, O.; Warnke, R.; Botstein, D.; Brown, P.O.; Levy, R. Variation in gene expression patterns in follicular lymphoma and the response to rituximab, Proc. Natl Acad. Sci. USA, Volume 100 (2003), pp. 1926-1930","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key2025102316275417624_19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/sonc.2002.30145","article-title":"Rituximab: Ongoing and future clinical development","volume":"29","author":"Grillo-Lopez, A.J.","year":"2002","unstructured":"[19] Grillo-Lopez, A.J.; Hedrick, E.; Rashford, M.; Benyunes, M. Rituximab: Ongoing and future clinical development, Semin. Oncol., Volume 29 (2002), pp. 105-112","journal-title":"Semin. Oncol."},{"key":"key2025102316275417624_20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.bmt.1704742","article-title":"Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia","volume":"35","author":"Lim, S.H.","year":"2005","unstructured":"[20] Lim, S.H.; Zhang, Y.; Wang, Z.; Esler, W.V.; Beggs, D.; Pruitt, B.; Hancock, P.; Townsend, M. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia, Bone Marrow Transplant., Volume 35 (2005), pp. 207-208","journal-title":"Bone Marrow Transplant."},{"key":"key2025102316275417624_21","first-page":"74","article-title":"Preclinical and phase I and II trials of rituximab","volume":"26","author":"Maloney, D.G.","year":"1999","unstructured":"[21] Maloney, D.G. Preclinical and phase I and II trials of rituximab, Semin. Oncol., Volume 26 (1999), pp. 74-78","journal-title":"Semin. Oncol."},{"key":"key2025102316275417624_22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma \u2013 half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin, P.","year":"1998","unstructured":"[22] McLaughlin, P.; Grillolopez, A.J.; Link, B.K.; Levy, R.; Czuczman, M.S.; Williams, M.E.; Heyman, M.R.; Bencebruckler, I.; White, C.A.; Cabanillas, F.; Jain, V.; Ho, A.D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma \u2013 half of patients respond to a four-dose treatment program, J. Clin. Oncol., Volume 16 (1998), pp. 2825-2833","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_23","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (idec-c2b8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein, N.L.","year":"1998","unstructured":"[23] Berinstein, N.L.; Grillolopez, A.J.; White, C.A.; Bencebruckler, I.; Maloney, D.; Czuczman, M.; Green, D.; Rosenberg, J.; McLaughlin, P.; Shen, D. Association of serum rituximab (idec-c2b8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma, Ann. Oncol., Volume 9 (1998), pp. 995-1001","journal-title":"Ann. Oncol."},{"key":"key2025102316275417624_24","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","article-title":"Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders","volume":"23","author":"Gordan, L.N.","year":"2005","unstructured":"[24] Gordan, L.N.; Grow, W.B.; Pusateri, A.; Douglas, V.; Mendenhall, N.P.; Lynch, J.W. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders, J. Clin. Oncol., Volume 23 (2005), pp. 1096-1102","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_25","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment","volume":"18","author":"Davis, T.A.","year":"2000","unstructured":"[25] Davis, T.A.; Grillo-Lopez, A.J.; White, C.A.; McLaughlin, P.; Czuczman, M.S.; Link, B.K.; Maloney, D.G.; Weaver, R.L.; Rosenberg, J.; Levy, R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment, J. Clin. Oncol., Volume 18 (2000), pp. 3135-3143","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.thj.6200559","article-title":"Second treatment with rituximab in b-cell non-Hodgkin's lymphoma: Efficacy and toxicity on 41 patients treated at CHU Lyon Sud","volume":"5","author":"Lemieux, B.","year":"2004","unstructured":"[26] Lemieux, B.; Bouafia, F.; Thieblemont, C.; Hequet, O.; Arnaud, P.; Tartas, S.; Traulle, C.; Salles, G.; Coiffier, B. Second treatment with rituximab in b-cell non-Hodgkin's lymphoma: Efficacy and toxicity on 41 patients treated at CHU Lyon Sud, Hematol. J., Volume 5 (2004), pp. 467-471","journal-title":"Hematol. J."},{"key":"key2025102316275417624_27","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini, M.","year":"2004","unstructured":"[27] Ghielmini, M.; Schmitz, S.F.; Cogliatti, S.B.; Pichert, G.; Hummerjohann, J.; Waltzer, U.; Fey, M.F.; Betticher, D.C.; Martinelli, G.; Peccatori, F.; Hess, U.; Zucca, E.; Stupp, R.; Kovacsovics, T.; Helg, C.; Lohri, A.; Bargetzi, M.; Vorobiof, D.; Cerny, T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule, Blood, Volume 103 (2004), pp. 4416-4423","journal-title":"Blood"},{"key":"key2025102316275417624_28","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma \u2013 a randomized phase II trial of the Minnie Pearl cancer research network","volume":"23","author":"Hainsworth, J.D.","year":"2005","unstructured":"[28] Hainsworth, J.D.; Litchy, S.; Shaffer, D.W.; Lackey, V.L.; Grimaldi, M.; Greco, F.A. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma \u2013 a randomized phase II trial of the Minnie Pearl cancer research network, J. Clin. Oncol., Volume 23 (2005), pp. 1088-1095","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 16S","key":"key2025102316275417624_29","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1200\/jco.2005.23.16_suppl.6527","article-title":"Rituximab maintenance following a Rituximab-containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle-cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Hiddemann, W.","year":"2005","unstructured":"[29] Hiddemann, W.; Forstpointner, R.; Dreyling, M.; Gramatzki, M.; B\u00f6ck, H.-P.; Haenel, M.; Seymour, J.F.; Unterhalt, M. Rituximab maintenance following a Rituximab-containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle-cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG), J. Clin. Oncol., Volume 23 (2005) no. Suppl. 16S, p. 6527","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial","volume":"362","author":"Ardeshna, K.M.","year":"2003","unstructured":"[30] Ardeshna, K.M.; Smith, P.; Norton, A.; Hancock, B.W.; Hoskin, P.J.; MacLennan, K.A.; Marcus, R.E.; Jelliffe, A.; Hudson, G.V.; Linch, D.C. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial, Lancet, Volume 362 (2003), pp. 516-522","journal-title":"Lancet"},{"key":"key2025102316275417624_31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation","volume":"97","author":"Colombat, P.","year":"2001","unstructured":"[31] Colombat, P.; Salles, G.; Brousse, N.; Eftekhari, P.; Soubeyran, P.; Delwail, V.; Deconinck, E.; Haioun, C.; Foussard, C.; Sebban, C.; Stamatoullas, A.; Milpied, N.; Boue, F.; Taillan, B.; Lederlin, P.; Najman, A.; Thieblemont, C.; Montestruc, F.; Mathieu-Boue, A.; Benzohra, A.; Solal-Celigny, P. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation, Blood, Volume 97 (2001), pp. 101-106","journal-title":"Blood"},{"key":"key2025102316275417624_32","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth, J.D.","year":"2002","unstructured":"[32] Hainsworth, J.D.; Litchy, S.; Burris, H.A.; Scullin, D.C.; Corso, S.W.; Yardley, D.A.; Morrissey, L.; Greco, F.A. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma, J. Clin. Oncol., Volume 20 (2002), pp. 4261-4267","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_33","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus, R.","year":"2005","unstructured":"[33] Marcus, R.; Imrie, K.; Belch, A.; Cunningham, D.; Flores, E.; Catalano, J.; Solal-Celigny, P.; Offner, F.; Walewski, J.; Raposo, J.; Jack, A.; Smith, P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, Volume 105 (2005), pp. 1417-1423","journal-title":"Blood"},{"key":"key2025102316275417624_34","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: Results of a prospective randomized study of the German low-grade lymphoma study group","volume":"106","author":"Hiddemann, W.","year":"2005","unstructured":"[34] Hiddemann, W.; Kneba, M.; Dreyling, M.; Schmitz, N.; Lengfelder, E.; Schmits, R.; Reiser, M.; Metzner, B.; Harder, H.; Hegewisch-Becker, S.; Fischer, T.; Kropff, M.; Reis, H.E.; Freund, M.; Wormann, B.; Fuchs, R.; Planker, M.; Schimke, J.; Eimermacher, H.; Trumper, L.; Aldaoud, A.; Parwaresch, R.; Unterhalt, M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: Results of a prospective randomized study of the German low-grade lymphoma study group, Blood, Volume 106 (2005), pp. 3725-3732","journal-title":"Blood"},{"key":"key2025102316275417624_35","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Results of a prospective randomized open label phase-iii study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (r-mcp) versus mcp alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle-cell lymphoma","volume":"104","author":"Herold, M.","year":"2004","unstructured":"[35] Herold, M. et al. Results of a prospective randomized open label phase-iii study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (r-mcp) versus mcp alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle-cell lymphoma, Blood, Volume 104 (2004), p. 169a","journal-title":"Blood"},{"issue":"Suppl. 1","key":"key2025102316275417624_36","first-page":"49a","article-title":"Rituximab added to chvp+ifn improves the outcome of follicular lymphoma patients: First analysis of the gela-goelams fl-2000 randomized trial","volume":"104","author":"Salles, G.","year":"2004","unstructured":"[36] Salles, G.; Foussard, C.; Mounier, N.; Morschhauser, F.; Bosly, A.; Lamy, T.; Haioun, C.; Brice, P.; Boubadallah, R.; Rossi, J.-F.; Audhuy, B.; Ferm\u00e9, C.; Mahe, B.; Lederlin, P.; Sebban, C.; Colombat, P.; Xerri, L. Rituximab added to chvp+ifn improves the outcome of follicular lymphoma patients: First analysis of the gela-goelams fl-2000 randomized trial, Blood, Volume 104 (2004) no. Suppl. 1, p. 49a","journal-title":"Blood"},{"key":"key2025102316275417624_37","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (fcm) significantly increases the response rate and prolongs survival as compared to fcm alone in patients with relapsed and refractory follicular and mantle-cell lymphomas \u2013 results of a prospective randomized study of the German Low-Grade Lymphoma study group (GLSG)","volume":"104","author":"Forstpointner, R.","year":"2004","unstructured":"[37] Forstpointner, R.; Dreyling, M.; Repp, R.; Hermann, S.; Haenel, A.; Metzner, B.; Pott, C.; Hartmann, F.; Rothmann, F.; Rohrberg, R.; Boeck, H.P.; Wandt, H.; Unterhalt, M.; Hiddemann, W. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (fcm) significantly increases the response rate and prolongs survival as compared to fcm alone in patients with relapsed and refractory follicular and mantle-cell lymphomas \u2013 results of a prospective randomized study of the German Low-Grade Lymphoma study group (GLSG), Blood, Volume 104 (2004), pp. 3064-3071","journal-title":"Blood"},{"key":"key2025102316275417624_38","first-page":"169a","article-title":"Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: A phase III randomized intergroup clinical trial","volume":"104","author":"Van Oers, M.H.J.","year":"2004","unstructured":"[38] Van Oers, M.H.J.; Van Glabbeke, M.; Teodorovic, I.; Rozewicz, C.; Klasa, R.; Marcus, R.E.; Wolf, M.; Kimby, E.; Hagenbeek, A. Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: A phase III randomized intergroup clinical trial, Blood, Volume 104 (2004), p. 169a (Abstract 586)","journal-title":"Blood"},{"key":"key2025102316275417624_39","article-title":"Results of E1496: A phase-III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma","volume":"23","author":"Hochster, H.S.","year":"2004","unstructured":"[39] Hochster, H.S.; Weller, E.; Ryan, T.; Habermann, T.M.; Gascoyne, R.; Frankel, S.R.; Horning, S.J. Results of E1496: A phase-III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma, Proc Am. Soc. Clin. Oncol., Volume 23 (2004) (Abstract 556)","journal-title":"Proc Am. Soc. Clin. Oncol."},{"key":"key2025102316275417624_40","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a","volume":"6","author":"Davis, T.A.","year":"2000","unstructured":"[40] Davis, T.A.; Maloney, D.G.; Grillo-Lopez, A.J.; White, C.A.; Williams, M.E.; Weiner, G.J.; Dowden, S.; Levy, R. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a, Clin. Cancer Res., Volume 6 (2000), pp. 2644-2652","journal-title":"Clin. Cancer Res."},{"key":"key2025102316275417624_41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/sonc.2002.32747","article-title":"Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-alpha 2a and granulocyte-macrophage colony stimulating factor","volume":"29","author":"Kimby, E.","year":"2002","unstructured":"[41] Kimby, E. Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-alpha 2a and granulocyte-macrophage colony stimulating factor, Semin. Oncol., Volume 29 (2002), pp. 7-10","journal-title":"Semin. Oncol."},{"key":"key2025102316275417624_42","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1158\/1078-0432.CCR-04-0525","article-title":"Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study","volume":"10","author":"Eisenbeis, C.F.","year":"2004","unstructured":"[42] Eisenbeis, C.F.; Grainger, A.; Fischer, B.; Baiocchi, R.A.; Carrodeguas, L.; Roychowdhury, S.; Chen, L.; Banks, A.L.; Davis, T.; Young, D.; Kelbick, N.; Stephens, J.; Byrd, J.C.; Grever, M.R.; Caligiuri, M.A.; Porcu, P. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study, Clin. Cancer Res., Volume 10 (2004), pp. 6101-6110","journal-title":"Clin. Cancer Res."},{"key":"key2025102316275417624_43","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2402424","article-title":"Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils","volume":"16","author":"van der Kolk, L.E.","year":"2002","unstructured":"[43] van der Kolk, L.E.; de Haas, M.; Grillo-Lopez, A.J.; Baars, J.W.; van Oers, M.H.J. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils, Leukemia, Volume 16 (2002), pp. 693-699","journal-title":"Leukemia"},{"key":"key2025102316275417624_44","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of idec-y2b8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma","volume":"17","author":"Witzig, T.E.","year":"1999","unstructured":"[44] Witzig, T.E.; White, C.A.; Wiseman, G.A.; Gordon, L.I.; Emmanouilides, C.; Raubitschek, A.; Janakiraman, N.; Gutheil, J.; Schilder, R.J.; Spies, S.; Silverman, D.H.S.; Parker, E.; Grillo-Lopez, A.J. Phase I\/II trial of idec-y2b8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma, J. Clin. Oncol., Volume 17 (1999), pp. 3793-3803","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_45","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase-II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"18","author":"Vose, J.M.","year":"2000","unstructured":"[45] Vose, J.M.; Wahl, R.L.; Saleh, M.; Rohatiner, A.Z.; Knox, S.J.; Radford, J.A.; Zelenetz, A.D.; Tidmarsh, G.F.; Stagg, R.J.; Kaminski, M.S. Multicenter phase-II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas, J. Clin. Oncol., Volume 18 (2000), pp. 1316-1323","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_46","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig, T.E.","year":"2002","unstructured":"[46] Witzig, T.E.; Gordon, L.I.; Cabanillas, F.; Czuczman, M.S.; Emmanouilides, C.; Joyce, R.; Pohlman, B.L.; Bartlett, N.L.; Wiseman, G.A.; Padre, N.; Grillo-Lopez, A.J.; Multani, P.; White, C.A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed b-cell non-Hodgkin's lymphoma, J. Clin. Oncol., Volume 20 (2002), pp. 2453-2463","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_47","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma","volume":"20","author":"Witzig, T.E.","year":"2002","unstructured":"[47] Witzig, T.E.; Flinn, I.W.; Gordon, L.I.; Emmanouilides, C.; Czuczman, M.S.; Saleh, M.N.; Cripe, L.; Wiseman, G.; Olejnik, T.; Multani, P.S.; White, C.A. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma, J. Clin. Oncol., Volume 20 (2002), pp. 3262-3269","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_48","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski, M.S.","year":"2001","unstructured":"[48] Kaminski, M.S.; Zelenetz, A.D.; Press, O.W.; Saleh, M.; Leonard, J.; Fehrenbacher, L.; Lister, T.A.; Stagg, R.J.; Tidmarsh, G.F.; Kroll, S.; Wahl, R.L.; Knox, S.J.; Vose, J.M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J. Clin. Oncol., Volume 19 (2001), pp. 3918-3928","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski, M.S.","year":"2005","unstructured":"[49] Kaminski, M.S.; Tuck, M.; Estes, J.; Kolstad, A.; Ross, C.W.; Zasadny, K.; Regan, D.; Kison, P.; Fisher, S.; Kroll, S.; Wahl, R.L. 131I-tositumomab therapy as initial treatment for follicular lymphoma, N. Engl. J. Med., Volume 352 (2005), pp. 441-449","journal-title":"N. Engl. J. Med."},{"key":"key2025102316275417624_50","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2003-01-0287","article-title":"A phase-2 trial of chop chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911","volume":"102","author":"Press, O.W.","year":"2003","unstructured":"[50] Press, O.W.; Unger, J.M.; Braziel, R.M.; Maloney, D.G.; Miller, T.P.; LeBlanc, M.; Gaynor, E.R.; Rivkin, S.E.; Fisher, R.I. A phase-2 trial of chop chemotherapy followed by tositumomab\/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911, Blood, Volume 102 (2003), pp. 1606-1612","journal-title":"Blood"},{"key":"key2025102316275417624_51","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier, B.","year":"2002","unstructured":"[51] Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van den Neste, E.; Salles, G.; Gaulard, P.; Reyes, F.; Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N. Engl. J. Med., Volume 346 (2002), pp. 235-242","journal-title":"N. Engl. J. Med."},{"key":"key2025102316275417624_52","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large b-cell lymphoma","volume":"23","author":"Feugier, P.","year":"2005","unstructured":"[52] Feugier, P.; Hoof, A.V.; Sebban, C.; Solal-Celigny, P.; Bouabdallah, R.; Ferm\u00e9, C.; Christian, B.; Lepage, E.; Tilly, H.; Morschhauser, F.; Gaulard, P.; Salles, G.; Bosly, A.; Gisselbrecht, C.; Reyes, F.; Coiffier, B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large b-cell lymphoma, J. Clin. Oncol., Volume 23 (2005), pp. 4117-4126","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_53","article-title":"Randomized intergroup trial of first line treatment for patients \u2a7d60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab \u2013 early stopping after the first interim analysis","volume":"23","author":"Pfreundschuh, M.G.","year":"2004","unstructured":"[53] Pfreundschuh, M.G.; Tr\u00fcmper, L.; Ma, D.; \u00d6sterborg, A.; Pettengell, R.; Trneny, M.; Shepherd, L.; Waleswski, J.; Zinzani, P.L.; Loeffler, M. Randomized intergroup trial of first line treatment for patients \u2a7d60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab \u2013 early stopping after the first interim analysis, Proc. Am. Soc. Clin. Oncol., Volume 23 (2004) (Abstract 556)","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"key2025102316275417624_54","first-page":"40a","article-title":"Rituximab-chop versus chop with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update","volume":"104","author":"Habermann, T.M.","year":"2004","unstructured":"[54] Habermann, T.M.; Weller, E.; Morrison, V.A.; Cassileth, P.A.; Cohn, J.; Dakhil, S.; Gascoyne, R.D.; Woda, B.; Fisher, R.; Peterson, B.A.; Horning, S.J. Rituximab-chop versus chop with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update, Blood, Volume 104 (2004), p. 40a","journal-title":"Blood"},{"key":"key2025102316275417624_55","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined chop plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn, L.H.","year":"2005","unstructured":"[55] Sehn, L.H.; Donaldson, J.; Chhanabhai, M.; Fitzgerald, C.; Gill, K.; Klasa, R.; MacPherson, N.; O'Reilly, S.; Spinelli, J.J.; Sutherland, J.; Wilson, K.S.; Gascoyne, R.D.; Connors, J.M. Introduction of combined chop plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia, J. Clin. Oncol., Volume 23 (2005), pp. 5027-5033","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_56","first-page":"7","article-title":"Best treatment of aggressive non-Hodgkin's lymphoma: A French perspective","volume":"18","author":"Coiffier, B.","year":"2005","unstructured":"[56] Coiffier, B.; Reye, F. Best treatment of aggressive non-Hodgkin's lymphoma: A French perspective, Oncology, Volume 18 (2005), pp. 7-15","journal-title":"Oncology"},{"key":"key2025102316275417624_57","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ncponc0229","article-title":"Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?","volume":"2","author":"Coiffier, B.","year":"2005","unstructured":"[57] Coiffier, B. Is bortezomib an effective treatment for indolent or mantle-cell non-Hodgkin's lymphoma?, Nat. Clin. Pract. Oncol., Volume 2 (2005), pp. 388-389","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"key2025102316275417624_58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.130.130","article-title":"Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed\/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial","volume":"104","author":"Morschhauser, F.","year":"2004","unstructured":"[58] Morschhauser, F.; Huglo, D.; Martinelli, G.; Paganelli, G.; Zinzani, P.L.; Hadjiyiannakis, D.; Liberati, A.; Illidge, T.; Milpied, N.; Stein, H.; Kalmus, J.; Morel, P.; Reimann, U.; Marcus, R. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed\/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: Results of an open-label phase II trial, Blood, Volume 104 (2004) (Abstract 130)","journal-title":"Blood"},{"key":"key2025102316275417624_59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase ii study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran, J.M.","year":"2000","unstructured":"[59] Foran, J.M.; Rohatiner, A.Z.S.; Cunningham, D.; Popescu, R.A.; Solal-Celigny, P.; Ghielmini, M.; Coiffier, B.; Johnson, P.W.M.; Gisselbrecht, C.; Reyes, F.; Radford, J.A.; Bessell, E.M.; Souleau, B.; Benzohra, A.; Lister, T.A. European phase ii study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma, J. Clin. Oncol., Volume 18 (2000), pp. 317-324","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_60","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase-II trial of the Minnie Pearl cancer research network","volume":"21","author":"Hainsworth, J.D.","year":"2003","unstructured":"[60] Hainsworth, J.D.; Litchy, S.; Barton, J.H.; Houston, G.A.; Hermann, R.C.; Bradof, J.E.; Greco, F.A. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase-II trial of the Minnie Pearl cancer research network, J. Clin. Oncol., Volume 21 (2003), pp. 1746-1751","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_61","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating, M.J.","year":"2005","unstructured":"[61] Keating, M.J.; O'Brien, S.; Albitar, M.; Lerner, S.; Plunkett, W.; Giles, F.; Andreeff, M.; Cortes, J.; Faderl, S.; Thomas, D.; Koller, C.; Wierda, W.; Detry, M.A.; Lynn, A.; Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia, J. Clin. Oncol., Volume 23 (2005), pp. 4079-4088","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_62","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1080\/1042819031000123555","article-title":"Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase","volume":"44","author":"Paydas, S.","year":"2003","unstructured":"[62] Paydas, S.; Yavuz, S.; Disel, U.; Sahin, B.; Ergin, M. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase, Leuk. Lymph., Volume 44 (2003), pp. 2165-2166","journal-title":"Leuk. Lymph."},{"key":"key2025102316275417624_63","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of malt type","volume":"102","author":"Conconi, A.","year":"2003","unstructured":"[63] Conconi, A.; Martinelli, G.; Thieblemont, C.; Ferreri, A.J.M.; Devizzi, L.; Peccatori, F.; Ponzoni, M.; Pedrinis, E.; Dell'Oro, S.; Pruneri, G.; Filipazzi, V.; Dietrich, P.Y.; Gianni, A.M.; Coiffier, B.; Cavalli, F.; Zucca, E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of malt type, Blood, Volume 102 (2003), pp. 2741-2745","journal-title":"Blood"},{"key":"key2025102316275417624_64","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd, J.C.","year":"2001","unstructured":"[64] Byrd, J.C.; Murphy, T.; Howard, R.S.; Lucas, M.S.; Goodrich, A.; Park, K.; Pearson, M.; Waselenko, J.K.; Ling, G.; Grever, M.R.; Grillo-Lopez, A.J.; Rosenberg, J.; Kunkel, L.; Flinn, I.W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity, J. Clin. Oncol., Volume 19 (2001), pp. 2153-2164","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_65","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O'Brien, S.M.","year":"2001","unstructured":"[65] O'Brien, S.M.; Kantarjian, H.; Thomas, D.A.; Giles, F.J.; Freireich, E.J.; Cortes, J.; Lerner, S.; Keating, M.J. Rituximab dose-escalation trial in chronic lymphocytic leukemia, J. Clin. Oncol., Volume 19 (2001), pp. 2165-2170","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd, J.C.","year":"2003","unstructured":"[66] Byrd, J.C.; Peterson, B.L.; Morrison, V.A.; Park, K.; Jacobson, R.; Hoke, E.; Vardiman, J.W.; Rai, K.; Schiffer, C.A.; Larson, R.A. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712), Blood, Volume 101 (2003), pp. 6-14","journal-title":"Blood"},{"key":"key2025102316275417624_67","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda, W.","year":"2005","unstructured":"[67] Wierda, W.; O'Brien, S.; Wen, S.; Faderl, S.; Garcia-Manero, G.; Thomas, D.; Do, K.A.; Cortes, J.; Koller, C.; Beran, M.; Ferrajoli, A.; Giles, F.; Lerner, S.; Albitar, M.; Kantarjian, H.; Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia, J. Clin. Oncol., Volume 23 (2005), pp. 4070-4078","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd, J.C.","year":"2005","unstructured":"[68] Byrd, J.C.; Rai, K.; Peterson, B.L.; Appelbaum, F.R.; Morrison, V.A.; Kolitz, J.E.; Shepherd, L.; Hines, J.D.; Schiffer, C.A.; Larson, R.A. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011, Blood, Volume 105 (2005), pp. 49-53","journal-title":"Blood"},{"issue":"Suppl. 1","key":"key2025102316275417624_69","first-page":"S96","article-title":"A novel, fully human, anti-cd20 monoclonal antibody. First clinical results from an ongoing phase i\/ii trial in patients with chronic lymphocytic leukemia","volume":"48","author":"Coiffier, B.","year":"2005","unstructured":"[69] Coiffier, B.; Tilly, H.; Pedersen, L.M.; Plesner, T.; Frederiksen, H.; Oers, M.H.J.v.; Wooldridge, J.; Klocsko, J.; Holowiecki, J.; Hellmann, A.; Walewski, J.; Petersen, J.; Flensburg, M.F.; Robak, T. A novel, fully human, anti-cd20 monoclonal antibody. First clinical results from an ongoing phase i\/ii trial in patients with chronic lymphocytic leukemia, Leuk. Lymph., Volume 48 (2005) no. Suppl. 1, p. S96 (Abstract P111)","journal-title":"Leuk. Lymph."},{"key":"key2025102316275417624_70","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (campath-1h) in patients who have failed fludarabine: Results of a large international study","volume":"99","author":"Keating, M.J.","year":"2002","unstructured":"[70] Keating, M.J.; Flinn, I.; Jain, V.; Binet, J.L.; Hillmen, P.; Byrd, J.; Albitar, M.; Brettman, L.; Santabarbara, P.; Wacker, B.; Rai, K.R. Therapeutic role of alemtuzumab (campath-1h) in patients who have failed fludarabine: Results of a large international study, Blood, Volume 99 (2002), pp. 3554-3561","journal-title":"Blood"},{"key":"key2025102316275417624_71","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase-II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1h) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin, J.","year":"2002","unstructured":"[71] Lundin, J.; Kimby, E.; Bjorkholm, M.; Broliden, P.A.; Celsing, F.; Hjalmar, V.; Mollgard, L.; Rebello, P.; Hale, G.; Waldmann, H.; Mellstedt, H.; Osterborg, A. Phase-II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1h) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL), Blood, Volume 100 (2002), pp. 768-773","journal-title":"Blood"},{"key":"key2025102316275417624_72","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial","volume":"101","author":"Ekstrand, B.C.","year":"2003","unstructured":"[72] Ekstrand, B.C.; Lucas, J.B.; Horwitz, S.M.; Fan, Z.; Breslin, S.; Hoppe, R.T.; Natkunam, Y.; Bartlett, N.L.; Horning, S.J. Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial, Blood, Volume 101 (2003), pp. 4285-4289","journal-title":"Blood"},{"key":"key2025102316275417624_73","article-title":"Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase-II study","author":"Choquet, S.","year":"2005","unstructured":"[73] Choquet, S.; Leblond, V.; Herbrecht, R.; Socie, G.; Stoppa, A.M.; Vandenberghe, P.; Fischer, A.; Morschhauser, F.; Salles, G.; Feremans, W.; Vilmer, E.; Peraldi, M.N.; Lang, P.; Lebranchu, Y.; Oksenhendler, E.; Garnier, J.L.; Lamy, T.; Jaccard, A.; Ferrant, A.; Offner, F.; Hermine, O.; Moreau, A.; Fafi-Kremer, S.; Morand, P.; Chatenoud, L.; Berriot-Varoqueaux, N.; Bergougnoux, L.; Milpied, N. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicentre phase-II study, Blood (2005) (on line)","journal-title":"Blood"},{"key":"key2025102316275417624_74","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase-3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: Aids-malignancies consortium trial 010","volume":"106","author":"Kaplan, L.D.","year":"2005","unstructured":"[74] Kaplan, L.D.; Lee, J.Y.; Ambinder, R.F.; Sparano, J.A.; Cesarman, E.; Chadburn, A.; Levine, A.M.; Scadden, D.T. Rituximab does not improve clinical outcome in a randomized phase-3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: Aids-malignancies consortium trial 010, Blood, Volume 106 (2005), pp. 1538-1543","journal-title":"Blood"},{"key":"key2025102316275417624_75","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin, J.","year":"2003","unstructured":"[75] Lundin, J.; Hagberg, H.; Repp, R.; Cavallin-Stahl, E.; Freden, S.; Juliusson, G.; Rosenblad, E.; Tjonnfjord, G.; Wiklund, T.; Osterborg, A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome, Blood, Volume 101 (2003), pp. 4267-4272","journal-title":"Blood"},{"key":"key2025102316275417624_76","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas: phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1h) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"103","author":"Enblad, G.","year":"2004","unstructured":"[76] Enblad, G.; Hagberg, H.; Erlanson, M.; Lundin, J.; MacDonald, A.P.; Repp, R.; Schetelig, J.; Seipelt, G.; Osterborg, A.; Lundin, J.; Kimby, E.; Bjorkholm, M.; Broliden, P.A.; Celsing, F.; Hjalmar, V.; Mollgard, L.; Rebello, P.; Hale, G.; Waldmann, H.; Mellstedt, H.; Osterborg, A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas: phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (campath-1h) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL), Blood, Volume 103 (2004), pp. 2920-2924","journal-title":"Blood"},{"key":"key2025102316275417624_77","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen, E.","year":"2001","unstructured":"[77] Olsen, E.; Duvic, M.; Frankel, A.; Kim, Y.; Martin, A.; Vonderheid, E.; Jegasothy, B.; Wood, G.; Gordon, M.; Heald, P.; Oseroff, A.; Pinter-Brown, L.; Bowen, G.; Kuzel, T.; Fivenson, D.; Foss, F.; Glode, M.; Molina, A.; Knobler, E.; Stewart, S.; Cooper, K.; Stevens, S.; Craig, F.; Reuben, J.; Bacha, P. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma, J. Clin. Oncol., Volume 19 (2001), pp. 376-388","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_78","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni, A.M.","year":"2003","unstructured":"[78] Gianni, A.M.; Magni, M.; Martelli, M.; Di Nicola, M.; Carlo-Stella, C.; Pilotti, S.; Rambaldi, A.; Cortelazzo, S.; Patti, C.; Parvis, G.; Benedetti, F.; Capria, S.; Corradini, P.; Tarella, C.; Barbui, T. Long-term remission in mantle-cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen), Blood, Volume 102 (2003), pp. 749-755","journal-title":"Blood"},{"key":"key2025102316275417624_79","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/annonc\/mdh090","article-title":"Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: A single institution study","volume":"15","author":"Belhadj, K.","year":"2004","unstructured":"[79] Belhadj, K.; Delfau-Larue, M.H.; Elgnaoui, T.; Beaujean, F.; Beaumont, J.L.; Pautas, C.; Gaillard, I.; Kirova, Y.; Allain, A.; Gaulard, P.; Farcet, J.P.; Reyes, F.; Haioun, C. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: A single institution study, Ann. Oncol., Volume 15 (2004), pp. 504-510","journal-title":"Ann. Oncol."},{"key":"key2025102316275417624_80","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2003-04-1257","article-title":"Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","volume":"103","author":"Horwitz, S.M.","year":"2004","unstructured":"[80] Horwitz, S.M.; Negrin, R.S.; Blume, K.G.; Breslin, S.; Stuart, M.J.; Stockerl-Goldstein, K.E.; Johnston, L.J.; Wong, R.M.; Shizuru, J.A.; Horning, S.J. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma, Blood, Volume 103 (2004), pp. 777-783","journal-title":"Blood"},{"key":"key2025102316275417624_81","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.seminoncol.2003.12.008","article-title":"Clearing minimal residual disease with rituximab consolidation therapy","volume":"31","author":"Brugger, W.","year":"2004","unstructured":"[81] Brugger, W. Clearing minimal residual disease with rituximab consolidation therapy, Semin. Oncol., Volume 31 (2004), pp. 33-37","journal-title":"Semin. Oncol."},{"key":"key2025102316275417624_82","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas","volume":"346","author":"Press, O.W.","year":"1995","unstructured":"[82] Press, O.W.; Eary, J.F.; Appelbaum, F.R.; Martin, P.J.; Nelp, W.B.; Glenn, S.; Fisher, D.R.; Porter, B.; Matthews, D.C.; Gooley, T.; Bernstein, I.D. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas, Lancet, Volume 346 (1995), pp. 336-340","journal-title":"Lancet"},{"key":"key2025102316275417624_83","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed b-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue","volume":"16","author":"Liu, S.Y.","year":"1998","unstructured":"[83] Liu, S.Y.; Eary, J.F.; Petersdorf, S.H.; Martin, P.J.; Maloney, D.G.; Appelbaum, F.R.; Matthews, D.C.; Bush, S.A.; Durack, L.D.; Fisher, D.R.; Gooley, T.A.; Bernstein, I.D.; Press, O.W. Follow-up of relapsed b-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue, J. Clin. Oncol., Volume 16 (1998), pp. 3270-3278","journal-title":"J. Clin. Oncol."},{"key":"key2025102316275417624_84","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press, O.W.","year":"2000","unstructured":"[84] Press, O.W.; Eary, J.F.; Gooley, T.; Gopal, A.K.; Liu, S.; Rajendran, J.G.; Maloney, D.G.; Petersdorf, S.; Bush, S.A.; Durack, L.D.; Martin, P.J.; Fisher, D.R.; Wood, B.; Borrow, J.W.; Porter, B.; Smith, J.P.; Matthews, D.C.; Appelbaum, F.R.; Bernstein, I.D. A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas, Blood, Volume 96 (2000), pp. 2934-2942","journal-title":"Blood"},{"key":"key2025102316275417624_85","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle-cell lymphoma","volume":"99","author":"Gopal, A.K.","year":"2002","unstructured":"[85] Gopal, A.K.; Rajendran, J.G.; Petersdorf, S.H.; Maloney, D.G.; Eary, J.F.; Wood, B.L.; Gooley, T.A.; Bush, S.A.; Durack, L.D.; Martin, P.J.; Matthews, D.C.; Appelbaum, F.R.; Bernstein, I.D.; Press, O.W. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle-cell lymphoma, Blood, Volume 99 (2002), pp. 3158-3162","journal-title":"Blood"},{"key":"key2025102316275417624_86","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee, A.","year":"2005","unstructured":"[86] Nademanee, A.; Forman, S.; Molina, A.; Fung, H.; Smith, D.; Dagis, A.; Kwok, C.; Yamauchi, D.; Anderson, A.L.; Falk, P.; Krishnan, A.; Kirschbaum, M.; Kogut, N.; Nakamura, R.; O'Donnell, M.; Parker, P.; Popplewell, L.; Pullarkat, V.; Rodriguez, R.; Sahebi, F.; Smith, E.; Snyder, D.; Stein, A.; Spielberger, R.; Zain, J.; White, C.; Raubitschek, A. A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma, Blood, Volume 106 (2005), pp. 2896-2902","journal-title":"Blood"},{"key":"key2025102316275417624_87","article-title":"Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone \u2013 results of a prospective randomized study of the German Low Grade Lymphoma study group (GLSG)","author":"Hiddemann, W.","year":"2005","unstructured":"[87] Hiddemann, W.; Kneba, M.; Dreyling, M.; Schmitz, N.; Lengfelder, E.; Schmits, R.; Reiser, M.; Metzner, B.; Harder, H.; Hegewisch-Becker, S.; Fischer, T.; Kropff, M.; Reis, H.E.; Freund, M.; Wormann, B.; Fuchs, R.; Planker, M.; Schimke, J.; Eimermacher, H.; Trumper, L.; Aldaoud, A.; Parwaresch, R.; Unterhalt, M. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone \u2013 results of a prospective randomized study of the German Low Grade Lymphoma study group (GLSG), Blood (2005)","journal-title":"Blood"}],"container-title":["Comptes Rendus. Biologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/item\/10.1016\/j.crvi.2005.12.006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:32:28Z","timestamp":1761229948000},"score":1,"resource":{"primary":{"URL":"https:\/\/comptes-rendus.academie-sciences.fr\/biologies\/articles\/10.1016\/j.crvi.2005.12.006\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,20]]},"references-count":87,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006]]}},"alternative-id":["10.1016\/j.crvi.2005.12.006"],"URL":"https:\/\/doi.org\/10.1016\/j.crvi.2005.12.006","relation":{},"ISSN":["1631-0691","1768-3238"],"issn-type":[{"value":"1631-0691","type":"print"},{"value":"1768-3238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,20]]}}}